Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q28444976)
Watch
English
PTEN Loss
genetic variant
LOSS
In more languages
edit
Statements
instance of
Loss Of Function Variant
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/214
chromosome
human chromosome 10
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/214
genomic start
89622870
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/214
genomic end
89731687
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/214
biological variant of
PTEN
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/214
positive therapeutic predictor for
temsirolimus
medical condition treated
prostate cancer
determination method
CIViC evidence level D
rating
CIViC 4-star trust rating
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/507
stated in
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
everolimus
medical condition treated
Her2-receptor positive breast cancer
determination method
CIViC evidence level B
rating
CIViC 4-star trust rating
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1297
stated in
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
temsirolimus
medical condition treated
endometrial cancer
determination method
CIViC evidence level D
rating
CIViC 3-star trust rating
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1614
stated in
PI3K pathway dependencies in endometrioid endometrial cancer cell lines
everolimus
medical condition treated
cancer
statement disputed by
Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/5840
stated in
Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
pictilisib
determination method
CIViC evidence level D
rating
CIViC 3-star trust rating
medical condition treated
Her2-receptor positive breast cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/2045
stated in
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models
pictilisib
determination method
CIViC evidence level D
rating
CIViC 2-star trust rating
medical condition treated
breast cancer
statement disputed by
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/2074
stated in
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models
carboplatin / paclitaxel / buparlisib combination therapy
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/714
stated in
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.
negative therapeutic predictor for
trastuzumab
medical condition treated
Her2-receptor positive breast cancer
statement disputed by
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1386
stated in
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
cetuximab
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
colorectal cancer
2 references
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/506
stated in
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/6315
stated in
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
everolimus
determination method
CIViC evidence level B
rating
CIViC 4-star trust rating
medical condition treated
bladder carcinoma
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/644
stated in
PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
trastuzumab
determination method
CIViC evidence level B
rating
CIViC 1-star trust rating
medical condition treated
breast cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/645
stated in
Therapeutic targeting of cancers with loss of PTEN function
temsirolimus
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
endometrial cancer
statement disputed by
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/893
stated in
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer
ridaforolimus
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
endometrial cancer
statement disputed by
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/893
stated in
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer
trastuzumab
determination method
CIViC evidence level D
rating
CIViC 2-star trust rating
medical condition treated
Her2-receptor positive breast cancer
2 references
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1383
stated in
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/8274
stated in
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
trastuzumab
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
Her2-receptor positive breast cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1385
stated in
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
cisplatin
determination method
CIViC evidence level D
rating
CIViC 2-star trust rating
medical condition treated
ovarian cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1492
stated in
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line
chemotherapy
determination method
CIViC evidence level B
rating
CIViC 2-star trust rating
medical condition treated
stomach carcinoma
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1493
stated in
Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer
panitumumab
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
colorectal cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/6315
stated in
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
trastuzumab
determination method
CIViC evidence level B
rating
CIViC 2-star trust rating
medical condition treated
Her2-receptor positive breast cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/2035
stated in
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
trastuzumab
determination method
CIViC evidence level B
rating
CIViC 2-star trust rating
medical condition treated
breast cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/2043
stated in
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
vemurafenib
determination method
CIViC evidence level D
rating
CIViC 4-star trust rating
medical condition treated
melanoma
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/6271
stated in
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
ado-trastuzumab emtansine
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
Her2-receptor positive breast cancer
statement disputed by
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/8706
stated in
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
trastuzumab
determination method
CIViC evidence level B
rating
CIViC 2-star trust rating
medical condition treated
gastric adenocarcinoma
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/864
stated in
PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.
lapatinib
determination method
CIViC evidence level B
rating
CIViC 2-star trust rating
medical condition treated
gastric adenocarcinoma
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/864
stated in
PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.
lapatinib
determination method
CIViC evidence level D
rating
CIViC 4-star trust rating
medical condition treated
Her2-receptor positive breast cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/8275
stated in
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
negative prognostic predictor for
prostate cancer
determination method
CIViC evidence level B
rating
CIViC 4-star trust rating
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/643
stated in
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
Identifiers
CIViC variant ID
214
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/214
HGVS nomenclature
no value
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/214
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit